Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Other hematologic neoplasm 1

Conditions

Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Heart Diseases 3Vascular Diseases 2Small Cell Lung Carcinoma 2Cardiovascular Diseases 2Cardiotoxicity 2Triple Negative Breast Neoplasms 1Recurrence 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Cancer Resectable 1Ovarian Carcinosarcoma 1Neoplasms, Second Primary 1Myelodysplastic Syndromes 1Metabolic Diseases 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Immune-related Adverse Event 1Hematologic Neoplasms 1Heart Failure 1Esophageal Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Colorectal Neoplasms 1Colorectal Cancer Metastatic 1Carcinoma, Hepatocellular 1Cancer Therapy-related Cardiovascular Toxicity 1Breast Neoplasms 1Advanced Ovarian Cancer 1

Interventions

Immune Checkpoint Inhibitors 1Antineoplastic Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Immune-related Adverse Event × Antineoplastic Agents × Clear all
NCT06702566 2024-11-25

The Effect of Serum Ferritin in irAE

Tianjin Medical University Cancer Institute and Hospital

Phase NA Recruiting
1,500 enrolled
Other hematologic neoplasmOther solid neoplasm

Immune-related Adverse Event

Data powered by HemOnc (CC BY 4.0) Colophon âš¡